The trial was designed to test the effectiveness of Lymphoseek in identifying lymphatic tissue, and was conducted in 80 patients with either melanoma or breast cancer. Five treatment centers participated.
The trial found that Lymphoseek accurately recognized lymphatic tissue in 99% of the tissue identified by the drug. Pathology data of the lymph nodes marked by Lymphoseek confirmed cancer in 22.3% of the melanoma patients and 22.6% of the breast cancer patients, Neoprobe said.
Neoprobe nets financing, December 27, 2007
Neoprobe extends agreement with Ethicon, December 20, 2007
Neoprobe, Cardinal Health ink distribution deal, November 28, 2007
Neoprobe cuts loss on higher sales, October 31, 2007
Cardinal hires Philips executive, August 13, 2007
Copyright © 2008 AuntMinnie.com